The estimated Net Worth of Scott Gottlieb is at least $499 Тысяча dollars as of 15 December 2023. Scott Gottlieb owns over 3,000 units of Pfizer stock worth over $266,940 and over the last 9 years he sold PFE stock worth over $0. In addition, he makes $231,621 as Independent Director at Pfizer.
Sign up
Scott Gottlieb PFE stock SEC Form 4 insiders trading
Scott has made over 6 trades of the Pfizer stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 3,000 units of PFE stock worth $79,410 on 15 December 2023.
The largest trade he's ever made was buying 4,000 units of Pfizer stock on 9 May 2016 worth over $12,120. On average, Scott trades about 773 units every 126 days since 2016. As of 15 December 2023 he still owns at least 9,000 units of Pfizer stock.
You can see the complete history of Scott Gottlieb stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Scott Gottlieb biography
Dr. Scott Gottlieb M.D. serves as Independent Director of the Company. serves as Independent Director of the Company. Special Partner, New Enterprise Associates, Inc.’s Healthcare Investment Team and Resident Fellow of the American Enterprise Institute. Served as the 23rd Commissioner of the U.S. Food and Drug Administration (FDA) from 2017 to 2019. Prior to serving as Commissioner of the FDA, Dr. Gottlieb held several roles in the public and private sectors, including serving as a Venture Partner to New Enterprise Associates, Inc. from 2007 to 2017. Dr. Gottlieb’s expertise in health care, public policy and the biopharmaceutical industry is an asset to Pfizer. Through his work as a physician and his time at the FDA, Dr. Gottlieb has demonstrated an understanding of patient needs, the public policy environment and the rapidly changing dynamics of biopharmaceutical research and development.
What is the salary of Scott Gottlieb?
As the Independent Director of Pfizer, the total compensation of Scott Gottlieb at Pfizer is $231,621. There are 17 executives at Pfizer getting paid more, with Albert Bourla having the highest compensation of $17,929,000.
How old is Scott Gottlieb?
Scott Gottlieb is 47, he's been the Independent Director of Pfizer since 2019. There are 30 older and no younger executives at Pfizer. The oldest executive at Pfizer Inc. is Wyllie Don Cornwell, 72, who is the Independent Director.
What's Scott Gottlieb's mailing address?
Scott's mailing address filed with the SEC is 5200 ILLUMINA WAY, , SAN DIEGO, CA, 92122.
Insiders trading at Pfizer
Over the last 12 years, insiders at Pfizer have traded over $216,003,942 worth of Pfizer stock and bought 24,324 units worth $872,198 . The most active insiders traders include Shantanu Narayen, Ian C Read и James M Kilts. On average, Pfizer executives and independent directors trade stock every 12 days with the average trade being worth of $2,169,896. The most recent stock trade was executed by Jennifer B. Damico on 13 August 2024, trading 5,154 units of PFE stock currently worth $147,714.
What does Pfizer do?
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. The company was established in 1849 in New York by two German entrepreneurs, Charles Pfizer and his cousin Charles F. Erhart.
What does Pfizer's logo look like?
Complete history of Scott Gottlieb stock trades at Illumina Inc и Pfizer
Pfizer executives and stock owners
Pfizer executives and other stock owners filed with the SEC include:
-
Albert Bourla,
Chairman of the Board, Chief Executive Officer -
Frank D'Amelio,
Chief Financial Officer, Executive Vice President - Business Operations and Global Supply -
Mikael Dolsten,
Chief Scientific Officer, President - Worldwide Research, Development and Medical -
John Young,
Chief Business Officer, Group President -
Dr. Albert Bourla D.V.M., DVM, Ph.D.,
Chairman & CEO -
Frank A. D'Amelio,
CFO & Exec. VP -
Dr. Mikael Dolsten M.D., Ph.D.,
Chief Scientific Officer and Pres of Worldwide Research, Devel. & Medical -
Angela Hwang,
Group Pres of Biopharmaceuticals Group -
John D. Young,
Advisor -
Shantanu Narayen,
Lead Independent Director -
Wyllie Don Cornwell,
Independent Director -
Helen Hobbs,
Independent Director -
Suzanne Nora Johnson,
Independent Director -
Joseph Echevarria,
Independent Director -
James Kilts,
Independent Director -
Ronald Blaylock,
Independent Director -
Dan Littman,
Independent Director -
Scott Gottlieb,
Independent Director -
James Quincey,
Independent Director -
Susan Hockfield,
Independent Director -
Susan Desmond-Hellmann,
Director -
Gordon Loh,
Senior Vice President, Corporate Audit -
Jennifer Damico,
Senior Vice President, Principal Accounting Officer, Controller -
Sally Susman,
Chief Corporate Affairs Officer, Executive Vice President -
Alexander Mackenzie,
Executive Vice President, Chief Development Officer -
Douglas Lankler,
Executive Vice President, General Counsel -
Rady Johnson,
Chief Compliance, Quality and Risk Officer, Executive Vice President -
Lidia Fonseca,
Executive Vice President, Chief Technology Officer and Digital Officer -
Dawn Rogers,
Chief Human Resource Officer, Executive Vice President -
Angela Hwang,
Group President, Pfizer Biopharmaceuticals Group -
Rady A. Johnson,
Exec. VP and Chief Compliance, Quality & Risk Officer -
Douglas M. Lankler,
Exec. VP & Gen. Counsel -
Christopher J. Stevo CFA,
Sr. VP & Chief Investor Relations Officer -
Lidia L. Fonseca,
Exec. VP and Chief Digital & Technology Officer -
Jennifer B. Damico,
Sr. VP, Controller & Principal Accounting Officer -
Mike McDermott,
Chief Financial Officer -
William Pao,
Executive Vice President -
Stephen W Sanger,
Director -
Frances D Fergusson,
Director -
James C Smith,
Director -
Laurie J Olson,
Executive Vice President -
W Don Cornwell,
Director -
Loretta V Cangialosi,
Sr. Vice President, Controller -
Charles H Hill,
Executive Vice President -
Dennis A Ausiello,
Director -
Kirsten Lund Jurgensen,
Executive Vice President -
Ian C Read,
Chairman & CEO -
Freda C Lewis Hall,
Executive Vice President -
Aamir Malik,
Executive Vice President -
Christoffel Boshoff,
Executive Vice President -
Michael Goettler,
Group President -
Cyrus Taraporevala,
Director -
Iii William H Gray,
Director -
M Anthony Burns,
Director -
Cavan M. Redmond,
Group President -
Kristin C Peck,
Executive Vice President -
David S Simmons,
Business Unit President -
Geno J Germano,
Business Unit President -
Anthony J Maddaluna,
Executive Vice President -
Olivier Brandicourt,
Business Unit President -
Marc Tessier Lavigne,
Director -
George A Lorch,
Director -
Amy W Schulman,
Executive Vice President -
Constance J Horner,
Director -
Payal Sahni,
Executive Vice President -
William R Jr Carapezzi,
Executive Vice President -
Michael Mc Dermott,
Executive Vice President -
David M Denton,
Chief Financial Officer & EVP